[Severe Raynaud's phenomenon associated with interferon-beta therapy for multiple sclerosis: case report].
Interferon-beta (IFN-beta) is administered for treatment of multiple sclerosis (MS). We report on a woman with MS who presented with severe Raynaud's phenomenon, livedo-reticularis and digital necrosis two weeks after beginning therapy with IFN-beta. Symptoms improved after the IFN-beta was discontinued and anticoagulation associated with cyclophosphamide and corticoid were introduced. Raynaud's phenomenon is probably a side effect of IFN-beta therapy for multiple sclerosis.
Cruz
B A
BA
Faculdade de Medicina, Universidade Federal de Minas Gerais. borisc@net.cm.com.br
Queiroz
E D
ED
Nunes
S V
SV
Cruz Filho
A
A
Campos
G B
GB
Monteiro
E L
EL
Crivellari
H
H
D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005385:Fingers / Q000473:pathology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016899:Interferon-beta / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009336:Necrosis; D011928:Raynaud Disease / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D017445:Skin Diseases, Vascular / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology
D000276:Adjuvants, Immunologic; D000925:Anticoagulants; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016899:Interferon-beta